- Home
- CHRS vs CBNA Comparison
CHRS vs CBNA Comparison
Compare CHRS & CBNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- CBNA
- Stock Information
- Founded
- CHRS 2010
- CBNA 2006
- Country
- CHRS United States
- CBNA United States
- Employees
- CHRS N/A
- CBNA N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- CBNA
- Sector
- CHRS Health Care
- CBNA
- Exchange
- CHRS Nasdaq
- CBNA NYSE
- Market Cap
- CHRS 191.3M
- CBNA 159.8M
- IPO Year
- CHRS 2014
- CBNA 2024
- Fundamental
- Price
- CHRS $1.32
- CBNA $24.77
- Analyst Decision
- CHRS Strong Buy
- CBNA Buy
- Analyst Count
- CHRS 4
- CBNA 3
- Target Price
- CHRS $5.38
- CBNA $27.67
- AVG Volume (30 Days)
- CHRS 2.0M
- CBNA 26.2K
- Earning Date
- CHRS 03-12-2025
- CBNA 02-15-2025
- Dividend Yield
- CHRS N/A
- CBNA N/A
- EPS Growth
- CHRS N/A
- CBNA 135.51
- EPS
- CHRS N/A
- CBNA 4.49
- Revenue
- CHRS $304,340,000.00
- CBNA $49,968,000.00
- Revenue This Year
- CHRS $2.47
- CBNA N/A
- Revenue Next Year
- CHRS N/A
- CBNA N/A
- P/E Ratio
- CHRS N/A
- CBNA $5.51
- Revenue Growth
- CHRS 44.19
- CBNA 76.01
- 52 Week Low
- CHRS $0.66
- CBNA $20.10
- 52 Week High
- CHRS $2.87
- CBNA $27.56
- Technical
- Relative Strength Index (RSI)
- CHRS 41.91
- CBNA N/A
- Support Level
- CHRS $1.38
- CBNA N/A
- Resistance Level
- CHRS $1.60
- CBNA N/A
- Average True Range (ATR)
- CHRS 0.12
- CBNA 0.00
- MACD
- CHRS -0.03
- CBNA 0.00
- Stochastic Oscillator
- CHRS 1.10
- CBNA 0.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About CBNA CHAIN BRIDGE BANCORP INC
Chain Bridge Bancorp Inc is engaged in banking industry. It offers commercial and personal banking services, including deposits, treasury management, payments, loans, commercial lending, residential mortgage financing, consumer loans, trusts and estate administration, wealth management, and asset custody.